CTNNB1 and hepatocellular carcinoma: In another study, none of 10 HCC patients with CTNNB1 or AXIN1 alterations responded to the anti-PD-(L)1 agent, while 53% (9/17) of patients without WNT/β-catenin pathway alterations attained durable stable disease as the best response, indicating that aberrant WNT/β-catenin pathway alterations may enhance immune evasion and resistance to anti-PD-(L)1 therapy (28).